Table 1.

Study overview

Populations (study abbreviation)	NCT number	Phase	First dose	No. of doses (months)a	Placebo	TVCb				References
						RZV		Placebo
						18–49	≥ 50	18–49	≥ 50
Autologous hematopoietic cell transplant recipients (auto-HSCT[III])	NCT01610414	III	After transplantation	2 (month 0, 2)	Sucrose reconstituted with saline	230	692	229	695	[42]
Hematologic malignancies (HM)	NCT01767467	III	During or after therapy	2 (month 0, 2)	Sucrose reconstituted with saline	74	209	73	206	[43]
Renal transplant recipients (RT)	NCT02058589	III	After therapy	2 (month 0, 2)	Sucrose reconstituted with saline	48	84	49	83	[45]
Patients with solid tumors (ST)	NCT01798056	II/III	During or after therapy	2 (month 0, 2)	Sucrose reconstituted with saline	31	86	30	85	[46]
Autologous hematopoietic cell transplant recipients (auto-HSCT[I/II])	NCT00920218	I/II	After transplantation	2a (month 1, 3)	Saline	4	25	–	–	[47]
				3a (month 0, 1, 3)		10	20	4	26
HIV-infected participants (HIV)	NCT01165203	I/II	At study initiation	3 (month 0, 2, 6)	Saline	46	28	34	15	[48]

HIV human immunodeficiency virus, RZV adjuvanted recombinant zoster vaccine, TVC total vaccinated cohort

^aStudy participants in the auto-HSCT(III), RT, HM, and ST studies received two intramuscular doses of either RZV or saline placebo, with the second dose administered 1–2 months after the first vaccination. Participants in the auto-HSCT(I/II) study were stratified into four groups. One group received three doses of glycoprotein E/AS01_E, and was not included in the analyses presented in this manuscript. The subgroups included in this manuscript received two doses of RZV (at months 1 and 3), three doses of RZV (at months 0, 1, and 3), or three doses of placebo (at months 0, 1, and 3). Participants in the HIV study received three doses of RZV or placebo at months 0, 2, and 6

^bAll data are reported for the total vaccinated cohort consisting of all participants who received at least one dose of RZV or placebo